Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer
Status:
Not yet recruiting
Trial end date:
2024-02-01
Target enrollment:
Participant gender:
Summary
This study will test whether enfortumab vedotin combined with pembrolizumab is an effective
treatment for people with bladder cancer (urothelial carcinoma) involving the lymph nodes who
are going to have surgery to remove their cancer (cystectomy). The researchers will look at
whether treatment with enfortumab vedotin and pembrolizumab before surgery can get rid of
cancer within the lymph nodes. They will also try to find out if this combination of drugs is
effective at shrinking participants' cancer before their surgery.
The researchers think that a combination of enfortumab vedotin and pembrolizumab may help
people with this disease because both drugs are designed to help the immune system attack and
kill cancer cells. The researchers think the drugs may be more effective if given in
combination rather than on their own.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborators:
Astellas Pharma US, Inc. Merck Sharp & Dohme Corp. Seagen Inc.